Beyond oncology--application of HPMA copolymers in non-cancerous diseases

Adv Drug Deliv Rev. 2010 Feb 17;62(2):258-71. doi: 10.1016/j.addr.2009.10.006. Epub 2009 Nov 10.

Abstract

Macromolecular drug conjugates have been developed to improve the efficacy and safety profile of various therapeutic agents for many years. Among them, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates are the most extensively studied delivery platforms for the effective treatment of cancer. In recent years, the applications of HPMA copolymers for the treatment of a broader range of non-cancerous diseases have also been explored. This review highlights the recent developments in the rational design, synthesis, and evaluation of novel HPMA copolymer-drug conjugates for non-cancerous diseases, such as musculoskeletal diseases, infectious diseases and spinal cord injury. The translation potential of these applications is also briefly discussed.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Acrylamides / chemical synthesis
  • Acrylamides / chemistry
  • Acrylamides / therapeutic use*
  • Animals
  • Arthritis, Rheumatoid / drug therapy
  • Humans
  • Nanomedicine* / methods
  • Neoplasms / drug therapy
  • Osteoporosis / drug therapy
  • Polymers / chemical synthesis
  • Polymers / chemistry
  • Polymers / therapeutic use*

Substances

  • Acrylamides
  • Polymers
  • N-(2-hydroxypropyl)methacrylamide